These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 21295173

  • 21. Evidence-based initiation of warfarin (Coumadin).
    Ebell MH.
    Am Fam Physician; 2005 Feb 15; 71(4):763-5. PubMed ID: 15742915
    [No Abstract] [Full Text] [Related]

  • 22. What are the thromboembolic risks of heart failure combined with chronic or paroxysmal AF?
    Caldwell JC, Mamas MA, Neyses L, Garratt CJ.
    J Card Fail; 2010 Apr 15; 16(4):340-7. PubMed ID: 20350702
    [Abstract] [Full Text] [Related]

  • 23. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS.
    Saudi Med J; 2004 Jul 15; 25(7):848-51. PubMed ID: 15235686
    [Abstract] [Full Text] [Related]

  • 24. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.
    Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD.
    Am Heart J; 2009 Aug 15; 158(2):252-6. PubMed ID: 19619702
    [Abstract] [Full Text] [Related]

  • 25. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs.
    Garcia DA, Lopes RD, Hylek EM.
    Thromb Haemost; 2010 Dec 15; 104(6):1099-105. PubMed ID: 20886196
    [Abstract] [Full Text] [Related]

  • 26. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA.
    N Engl J Med; 1999 Mar 25; 340(12):901-7. PubMed ID: 10089183
    [Abstract] [Full Text] [Related]

  • 27. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
    Ripley TL, Harrison D, Germany RE, Adamson PB.
    Clin Ther; 2010 Mar 25; 32(3):506-14. PubMed ID: 20399987
    [Abstract] [Full Text] [Related]

  • 28. Evidence-based adjustment of warfarin (Coumadin) doses.
    Ebell MH.
    Am Fam Physician; 2005 May 15; 71(10):1979-82. PubMed ID: 15926414
    [No Abstract] [Full Text] [Related]

  • 29. Peri-operative anticoagulant therapy--the case for an uninterrupted dose-adjusted warfarin regimen in the high-risk patient.
    Franz RC.
    S Afr J Surg; 2006 Aug 15; 44(3):84, 86. PubMed ID: 16958233
    [No Abstract] [Full Text] [Related]

  • 30. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD, Johnson JA, Turpie AG.
    Arch Intern Med; 2004 Jun 28; 164(12):1319-26. PubMed ID: 15226166
    [Abstract] [Full Text] [Related]

  • 31. [Anticoagulation in atrial fibrillation].
    Binggeli C, Brunckhorst CB.
    Herz; 2008 Feb 28; 33(1):13-9. PubMed ID: 18273573
    [Abstract] [Full Text] [Related]

  • 32. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice.
    Wittkowsky AK.
    Am J Manag Care; 2004 Oct 28; 10(10 Suppl):S297-306; discussion S312-7. PubMed ID: 15605700
    [Abstract] [Full Text] [Related]

  • 33. Thromboembolism and antithrombotic therapy in congestive heart failure.
    Dunkman WB.
    J Cardiovasc Risk; 1995 Apr 28; 2(2):107-17. PubMed ID: 7606647
    [Abstract] [Full Text] [Related]

  • 34. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.
    Phillips KW, Ansell J.
    Expert Rev Cardiovasc Ther; 2008 Jan 28; 6(1):57-70. PubMed ID: 18095907
    [Abstract] [Full Text] [Related]

  • 35. Managing mechanical valves with reduced anticoagulation.
    Slaughter MS, Jweied E.
    Expert Rev Cardiovasc Ther; 2007 Nov 28; 5(6):1073-85. PubMed ID: 18035923
    [Abstract] [Full Text] [Related]

  • 36. Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Seneviratne C, Kupfer Y, Tessler S.
    N Engl J Med; 2003 Jul 24; 349(4):398-400; author reply 398-400. PubMed ID: 12879892
    [No Abstract] [Full Text] [Related]

  • 37. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy.
    Kearon C.
    Clin Chest Med; 2010 Dec 24; 31(4):719-30. PubMed ID: 21047578
    [Abstract] [Full Text] [Related]

  • 38. Clinical inquiries. Does warfarin prevent venous thromboembolic events in aPL-positive patients?
    Mazzone MF, Jamieson B, Lo V.
    J Fam Pract; 2007 Apr 24; 56(4):309-11. PubMed ID: 17403331
    [No Abstract] [Full Text] [Related]

  • 39. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators.
    N Engl J Med; 2003 Apr 10; 348(15):1425-34. PubMed ID: 12601075
    [Abstract] [Full Text] [Related]

  • 40. Aspirin for atrial fibrillation.
    Douglas M, Strelnick A.
    J Fam Pract; 2000 Jan 10; 49(1):7-8. PubMed ID: 10678329
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.